Orion Oyj (ORINF)
USD 48.65
(0.0%)
USD 48.65
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 93.4 Million EUR | 178.75% |
| 2022 | -118.6 Million USD | 3.57% |
| 2021 | -122.98 Million EUR | 45.9% |
| 2020 | -227.33 Million EUR | -45.7% |
| 2019 | -156.02 Million EUR | -18.02% |
| 2018 | -132.2 Million EUR | -940.94% |
| 2017 | -12.7 Million EUR | 73.71% |
| 2016 | -48.3 Million EUR | 22.54% |
| 2015 | -62.35 Million EUR | -227.51% |
| 2014 | 48.9 Million EUR | 13.46% |
| 2013 | 43.1 Million EUR | 601.16% |
| 2012 | -8.6 Million EUR | 74.93% |
| 2011 | -34.3 Million EUR | -267.32% |
| 2010 | 20.5 Million EUR | 152.43% |
| 2009 | -39.1 Million EUR | -31.21% |
| 2008 | -29.8 Million EUR | 65.47% |
| 2007 | -86.3 Million EUR | 13.87% |
| 2006 | -100.2 Million EUR | 3.09% |
| 2005 | -103.4 Million EUR | -849.28% |
| 2004 | 13.8 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 95.82 Million EUR | -270.95% |
| 2024 Q2 | 111.2 Million EUR | 1610.77% |
| 2024 Q1 | 7.01 Million EUR | -93.03% |
| 2023 Q3 | 129.49 Million USD | -10.2% |
| 2023 Q2 | 144.19 Million USD | 20.08% |
| 2023 Q1 | 120.08 Million USD | 194.53% |
| 2023 Q4 | 103.08 Million EUR | -20.39% |
| 2023 FY | 93.4 Million EUR | 178.75% |
| 2022 Q4 | -127.03 Million USD | 14.77% |
| 2022 FY | -118.6 Million USD | 3.57% |
| 2022 Q1 | -126.8 Million EUR | -17.19% |
| 2022 Q2 | 175.54 Million EUR | 238.44% |
| 2022 Q3 | -149.06 Million EUR | -184.92% |
| 2021 Q2 | -60.71 Million EUR | 75.96% |
| 2021 Q4 | -108.2 Million EUR | -124.02% |
| 2021 Q3 | -48.3 Million EUR | 20.45% |
| 2021 Q1 | -252.57 Million EUR | -35.94% |
| 2021 FY | -122.98 Million EUR | 45.9% |
| 2020 Q1 | -157.7 Million EUR | -51.63% |
| 2020 FY | -227.33 Million EUR | -45.7% |
| 2020 Q2 | -25.5 Million EUR | 83.83% |
| 2020 Q3 | -115.2 Million EUR | -351.76% |
| 2020 Q4 | -185.8 Million EUR | -61.28% |
| 2019 FY | -156.02 Million EUR | -18.02% |
| 2019 Q4 | -104 Million EUR | -21.35% |
| 2019 Q2 | 10.8 Million EUR | 105.9% |
| 2019 Q3 | -85.7 Million EUR | -893.52% |
| 2019 Q1 | -182.9 Million EUR | -88.17% |
| 2018 Q1 | 113.3 Million EUR | 992.13% |
| 2018 FY | -132.2 Million EUR | -940.94% |
| 2018 Q4 | -97.2 Million EUR | -19.56% |
| 2018 Q3 | -81.3 Million EUR | -50.83% |
| 2018 Q2 | -53.9 Million EUR | -147.57% |
| 2017 Q1 | 60.3 Million EUR | 224.84% |
| 2017 FY | -12.7 Million EUR | 73.71% |
| 2017 Q4 | -12.7 Million EUR | -169.4% |
| 2017 Q3 | 18.3 Million EUR | -78.14% |
| 2017 Q2 | 83.7 Million EUR | 38.81% |
| 2016 Q1 | -96.6 Million EUR | -68.29% |
| 2016 FY | -48.3 Million EUR | 22.54% |
| 2016 Q4 | -48.3 Million EUR | -885.71% |
| 2016 Q3 | -4.9 Million EUR | -106.99% |
| 2016 Q2 | 70.1 Million EUR | 172.57% |
| 2015 Q3 | -500 Thousand EUR | -100.83% |
| 2015 FY | -62.35 Million EUR | -227.51% |
| 2015 Q4 | -57.4 Million EUR | -11380.0% |
| 2015 Q2 | 60.1 Million EUR | 173.74% |
| 2015 Q1 | -81.5 Million EUR | -266.67% |
| 2014 Q2 | 90.9 Million EUR | 30400.0% |
| 2014 Q3 | 64.3 Million EUR | -29.26% |
| 2014 Q4 | 48.9 Million EUR | -23.95% |
| 2014 FY | 48.9 Million EUR | 13.46% |
| 2014 Q1 | -300 Thousand EUR | -100.7% |
| 2013 Q2 | 154.6 Million EUR | 978.41% |
| 2013 Q1 | -17.6 Million EUR | -104.65% |
| 2013 FY | 43.1 Million EUR | 601.16% |
| 2013 Q4 | 43.1 Million EUR | -61.89% |
| 2013 Q3 | 113.1 Million EUR | -26.84% |
| 2012 Q3 | 35.6 Million EUR | -62.68% |
| 2012 Q2 | 95.4 Million EUR | 231.95% |
| 2012 Q1 | -72.3 Million EUR | -110.79% |
| 2012 FY | -8.6 Million EUR | 74.93% |
| 2012 Q4 | -8.6 Million EUR | -124.16% |
| 2011 Q2 | 45.3 Million EUR | 143.23% |
| 2011 Q3 | 12.9 Million EUR | -71.52% |
| 2011 Q4 | -34.3 Million EUR | -365.89% |
| 2011 Q1 | -104.8 Million EUR | -611.22% |
| 2011 FY | -34.3 Million EUR | -267.32% |
| 2010 FY | 20.5 Million EUR | 152.43% |
| 2010 Q3 | 5.9 Million EUR | -87.71% |
| 2010 Q4 | 20.5 Million EUR | 247.46% |
| 2010 Q1 | -70.2 Million EUR | -79.54% |
| 2010 Q2 | 48 Million EUR | 168.38% |
| 2009 FY | -39.1 Million EUR | -31.21% |
| 2009 Q4 | -39.1 Million EUR | 0.0% |
| 2008 FY | -29.8 Million EUR | 65.47% |
| 2007 FY | -86.3 Million EUR | 13.87% |
| 2006 Q4 | -100.2 Million EUR | 0.0% |
| 2006 FY | -100.2 Million EUR | 3.09% |
| 2005 FY | -103.4 Million EUR | -849.28% |
| 2004 FY | 13.8 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.74 Billion USD | 99.589% |
| Bristol-Myers Squibb Company PFD CONV 2 | 30 Billion USD | 99.689% |
| CSPC Pharmaceutical Group Limited | -1.59 Billion USD | 105.859% |
| Clarus Therapeutics Holdings, Inc. | 15.85 Million USD | -489.126% |
| Novartis AG | 12.95 Billion USD | 99.279% |
| PT Kalbe Farma Tbk. | -169.7 Million USD | 155.038% |